Thank you for contacting us! We will be in touch soon! In the meantime, feel free to continue browsing our site.
Events
- Breakfast & Biotech with Biocytogen | September 21, 2022
- Webinar: Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen | September 13, 2022
- Webinar: Preclinical Models to Investigate NK Cell-Targeted Immunotherapies | August 04, 2022
- 10th annual Immuno-Oncology Summit | August 02, 2022
- 18th International SCBA Symposium | July 26, 2022
- Basic Cardiovascular Sciences Scientific Sessions 2022 | July 19, 2022
News
- IWHM6 | Biocytogen to Present 12 Posters on Innovative Mouse and Rat Models | September 29, 2022
- Biocytogen to Present at BioJapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress | September 27, 2022
- Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy | September 15, 2022
- Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs | September 01, 2022
- US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab | August 30, 2022
- Biocytogen Expands Partnership with Merck | August 25, 2022
